147006-56-2

Usage

Uses

Used in Pharmaceutical Industry:
2,5-DIMETHYLQUINAZOLIN-4-OL is used as an antidepressant medication for the treatment of depression. It functions by inhibiting the reuptake of serotonin and noradrenaline, key neurotransmitters implicated in mood regulation, thus elevating their availability in the synaptic cleft and ameliorating depressive symptoms.
Additionally, 2,5-DIMETHYLQUINAZOLIN-4-OL is used as a potential treatment for insomnia and anxiety disorders due to its effects on neurotransmitter levels and its antagonistic action on certain serotonin receptors, which may contribute to improved sleep patterns and reduced anxiety.
It is typically administered orally in the form of tablets or capsules, with dosage and treatment duration tailored to the individual's specific condition and response to the medication. The use of 2,5-DIMETHYLQUINAZOLIN-4-OL should always be under the supervision of a healthcare professional to ensure safety, minimize side effects, and optimize therapeutic outcomes.

Upstream product

• 147006-55-1 4-amino-2,5-dimethylquinazoline 
• 56043-01-7 2-amino-6-methylbenzonitrile 
• 4389-50-8 2-amino-6-methylbenzoic acid 
• 108-24-7 acetic anhydride 
• 60288-19-9 2,5-dimethyl-4H-benzo[d][1,3]oxazin-4-one 
• 66232-41-5 6-methyl-2-acetylaminobenzoic acid 

Downstream Products

• 147006-57-3 4-chloro-2,5-dimethylquinazoline 
• 1123685-04-0 2-[(E)-2-(4-chlorophenyl)ethenyl]-5-methylquinazolin-4(3H)-one 
• 1123684-98-9 4-chloro-2-[(E)-2-(4-chlorophenyl)ethenyl]-5-methylquinazoline 
• 147006-60-8 3-methyl-2-(1H-imidazol-2-yl)aniline 

Relevant academic research and scientific papers

PIPERIDINE SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES WITH INHIBITORY ACTIVITY ON THE REPLICATION OF THE RESPIRATORY SYNCYTIAL VIRUS (RSV)

The invention concerns novel substituted bicyclic pyrazolo pyrimidine compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further conce

Synthesis and evaluation of quinazolines as inhibitors of the bacterial cell division protein FtsZ

The bacterial cell division protein FtsZ is one of many potential targets for the development of novel antibiotics. Recently, zantrin Z3 was shown to be a cross-species inhibitor of FtsZ; however, its specific interactions with the protein are still unknown. Herein we report the synthesis of analogues that contain a more tractable core structure and an analogue with single-digit micromolar inhibition of FtsZs GTPase activity, which represents the most potent inhibitor of Escherichia coli FtsZ reported to date. In addition, the zantrin Z3 core has been converted to two potential photo-cross-linking reagents for proteomic studies that could shed light on the molecular interactions between FtsZ and molecules related to zantrin Z3.

Synthesis and SAR optimization of quinazolin-4(3H)-ones as poly(ADP-ribose)polymerase-1 inhibitors

We have demonstrated that quinazolin-4(3H)-one, a nicotinamide (NI) mimic with PARP-1 inhibitory activity in the high micromolar range (IC50 = 5.75 μM) could be transformed into highly active derivatives with only marginal increase in molecular weight. Convenient one to two synthetic steps allowed us to explore extensive SAR at the 2-, and 5- through 8-positions of the quinazolin-4(3H)-one scaffold. Substitutions at the 2- and 8-positions were found to be most favorable for improved PARP-1 inhibition. The amino group at 8-position resulted in compound 22 with an IC50 value of 0.76 μM. Combination of the 8-amino substituent with an additional methyl substituent at the 2-position provided the most potent compound 31 [8-amino-2-methylquinazolin- 4(3H)-one, IC50 = 0.4 μM] in the present study. Compound 31 inhibited the proliferation of Brca1-deficient cells with an IC50 value of 49.0 μM and displayed >10-fold selectivity over wild type counterparts. Binding models of these derivatives within the active site of PARP-1 have further supported the SAR data and will be useful for future lead optimization efforts.

Discovery and structure-activity relationships of 4-aminoquinazoline derivatives, a novel class of opioid receptor like-1 (ORL1) antagonists

Synthesis and structure-activity relationship studies of a series of 4-aminoquinazoline derivatives led to the identification of (1R,2S)-17, N-[(1R,2S)-2-({2-[(4-chlorophenyl)carbonyl]amino-6-methylquinazolin-4-yl}amino)cyclohexyl]guanidine dihydrochloride, as a highly potent ORL1 antagonist with up to 3000-fold selectivity over the μ, δ, and κ opioid receptors. Molecular modeling clarified the structural factors contributing to the high affinity and selectivity of (1R,2S)-17.

Imidazodiazepine derivatives

The novel imidazodiazepine derivatives of the formula: STR1 wherein the substituents are as described in the specification, can be used for the control or prevention of epileptic seizures, anxiety, tension and excitation states, sleep disorders, schizophr

New Tetracyclic Derivatives of Imidazobenzodiazepines and of Imidazothienodiazepines

The synthesis of new tetracyclic 1,4-diazepine derivatives is described.In these compounds, an additional five-membered heterocycle is fused on the known tricyclic ring systems imidazobenzodiazepine and imidazothienodiazepine.Many of these new compounds display a very high affinity to the benzodiazepine receptor in mammals.